Reply to “Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach”
Crossref DOI link: https://doi.org/10.1186/s12885-024-12288-5
Published Online: 2024-07-22
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hui, Wen
Gao, Zhixiang
Zhu, Min
Wu, Huazhang
Cai, Yuanyi
Text and Data Mining valid from 2024-07-22
Version of Record valid from 2024-07-22
Article History
Received: 6 February 2024
Accepted: 19 April 2024
First Online: 22 July 2024
Declarations
:
: Not applicable.
: The authors declare no competing interests.